摘要
目的探讨P53、Livin和PARP在上皮性卵巢癌中表达以及与卵巢癌患者化疗耐药和临床预后间的相关性。方法选取2011年1月～2015年6月重庆市肿瘤研究所妇科经手术病理证实的卵巢上皮性癌标本74例为研究对象。对患者进行随访,根据复发情况分为化疗敏感组与化疗耐药组,对比2组间的耐药基因表达的差异性、生存率,并对生存时间的影响因素进行分析。结果P53、Livin和PARP在化疗敏感组的阳性率分别为47.1%、56.9%与52.9%,在化疗耐药组的阳性率分别为73.9%、95.7%与95.7%,组间比较各项在化疗敏感组的阳性率均低于化疗耐药组,差异具有统计学意义（P〈0.05）。化疗敏感组1年、3年、5年生存率分别为100.0%、82.4%与66.7%,化疗耐药组1年、3年、5年生存率分别为87.0%、26.1%与8.7%,组间比较化疗敏感组的各期生存率均高于化疗耐药组,差异具有统计学意义（P〈0.05）。Cox回归模型结果显示,临床分期、化疗敏感程度对生存时间有显著影响（P〈0.05）,是影响临床预后的重要因素。结论 P53、Livin和PARP的表达均与上皮性卵巢癌患者的化疗耐药性相关,因此可用来预测患者的化疗疗效,对于耐药基因高表达的患者,可给予个性化的应对方案,以改善患者预后。
Objective To explore the clinical expression of P53,Livin and PARP in the epithelial ovarian cancer and its correlation with the chemotherapy resistance and clinical prognosis.Methods 74 specimen of epithelial ovarian cancer confirmed from January 2009 to June 2011 in our gynecology department were selected.During the follow-up visit,the subjects were divided into chemotherapy sensitivity group and chemotherapy resistance group according to the recurrence cases,the clinical expression and survival rate for two groups were compared,the influence factors of survival time were analyzed.Results The positive rate of P53,Livin and PARP for chemotherapy sensitivity group was 47.1%,56.9% and 52.9%;the positive rate for chemotherapy resistance group was 73.9%,95.7% and 95.7%,the diyforences were significant（P〈0.05）.After 1,3 and 5 years of treatment,the survival rate for chemotherapy sensitivity group was 100.0%,82.4% and 66.7%,The survival rate for chemotherapy resistance group was 87.0%,26.1% and 8.7%,the diyforences were significant（P〈0.05）.Based on the Cox regression model,the influence factors of the patient＇s age,pathological differentiation degree,clinical staging and chemotherapy sensitivity were introduced.It was known that the patient＇s survival time was greatly influenced by clinical staging and chemotherapy sensitivity（P〈0.05）.Conclusion For patients with epithelial ovarian cancer,the expression of P53,Livin and PARP is correlated with chemotherapy resistance.Therefore,the clinical effect is predictable,for patients with higher expression,the personalized therapy can improve the patient＇s prognosis.
出处
《中国生化药物杂志》
CAS
2017年第2期294-296,共3页
Chinese Journal of Biochemical Pharmaceutics
